Triclisinone (2), a new ochnaflavone derivative, was isolated from the aerial parts of Triclisia gilletii, along with known drypemolundein B (1) and eight other known compounds. The chemical shifts of drypemolundein B (1) have been partially revised based on reinterpretation of NMR spectroscopic data. The eight other secondary metabolites are composed of: (+)-nonacosan-10-ol (3); stigmasterol (4), 3-O-β-D-glucopyranosylsitosterol (5), 3-O-β-D-glucopyranosylstigmasterol (6); oleanic acid (7); myricetin (8), quercetin (9) and 3-methoxyquercetin (10). Their structures were elucidated using IR, MS, NMR 1D and 2D, H andC and comparison with literature data. Furthermore, compounds 1, 2, 5, 6, 8, 9 and the crude extract were tested against Mycobacterium tuberculosis. Compounds 1, 2, 8 and 9 displayed moderate to very good activity against resistant strain (codified AC 45) of M. tuberculosis with minimum inhibitory concentrations MICs ranging from 3.90 to 62.5 μg/mL.

Context: The roots of Lophira lanceolata Van Tiegh. Ex Keay (Ochnaceae) have numerous medicinal values in the Central African region. Even though the MeOH extract of the roots has shown antimycobacterial activities, the constituents responsible for this inhibitory activity remain unknown.Objective: Phytochemical investigation of the MeOH root extract of L. lanceolata and determination of the antimycobacterial activities of that extract and constituents against the growth of Mycobacterium tuberculosis.Materials and methods: Column chromatography was used to provide bioactive phytoconstituents. Those compounds were elucidated using MS and NMR spectroscopic data. Antimycobacterial screening of the extract (4.882–5000 µg/mL in DMSO during 24 h at 37 °C) and isolated compounds (0.244–250 µg/mL in DMSO during 24 h at 37 °C) was performed by microplate alamar blue assay (MABA) against two mycobacterial strains.Results: The investigation of L. lanceolata MeOH roots extract provided of mixture of unseparated biflavonoids with a newly described one, dihydrolophirone A (1a) associated to lophirone A (1b). The bioactive compounds that effectively inhibited the growth of M. tuberculosis AC45 were found to be compounds 1 and 2. They exhibited MIC values of 31.25 and 15.75 µg/mL, respectively, and their MIC was found to be 62.5 µg/mL against resistant strain AC83.Discussion and conclusions: It is clearly evident from the results obtained that the mycobacterial activity of L. lanceolata could be related mainly to its steroid and flavonoid contents. Therefore, this study suggests the potential of the above-mentioned classes of compounds as promising candidate agents for developing new anti-tuberculosis drugs.

No abstract

No abstract

The non-Hodgkin's lymphomas (NHLs) are a diverse group of malignancies that originate in lymphoid cells, heterogeneous in clinical behavior, morphology, cellular origin, etiology, and pathogenesis. A viral infectious etiology had been associated with them. This study aimed to investigate the seroprevalence of Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV) among patients with NHL at the Yaoundé General Hospital (YGH). Participants for this cross-sectional study were recruited at the medical oncology unit from October 2018 to December 2019. For each patient fulfilling the inclusion criteria, five milliliters of blood were drawn at the crook of their elbows in EDTA tubes. Then, EBV, HIV, HBV, and HVC screening were done using the Rapid Diagnostic Tests (RDTs); Bio-Rad EBV, Alere Determine HIV-1/HIV-2, HBV the best diagnostic and HVC Wondfo biotech respectively. Participants were made up of sixty-three males (69.23%) and twenty-eight females (30.77%). Their ages ranged from nineteen to seventy-eight years, with a mean ± SD of 56.5 ± 15.5. There were eight HIV patients (8.8%) followed by five EBV or HBV patients (5.5%). Three patients were coinfected with HIV+EBV (3.3%) while only two patients (2.2%) had HCV. Only HIV and EBV were seen coinfected. The presence of HBV and HCV in patients with NHL reveals the need to understand how these viruses induce lymphoproliferative diseases, more precisely, the non-Hodgkin´s lymphoma.